Loading clinical trials...

A Multi-center, Randomized, Double-blind Phase III Clinical Trial to Assess and Compare to the Efficacy and Safety of Lafutidine, Famotidine and Omeprazole-referenced in Korean Erosive Esophagitis Patients | Clinical Trials | Clareo Health

COMPLETEDPHASE3

A Multi-center, Randomized, Double-blind Phase III Clinical Trial to Assess and Compare to the Efficacy and Safety of Lafutidine, Famotidine and Omeprazole-referenced in Korean Erosive Esophagitis Patients

NCT01499368•Boryung Pharmaceutical Co., Ltd

View on ClinicalTrials.gov

Summary

To evaluate the healing rate and safety of Lafutidine in erosive esophagitis

Eligibility

Age

20 - 75 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Patients who had symptoms of heartburn with a diagnosis of grade A to D reflux esophagitis according to the Los Angeles classification

Exclusion Criteria

•Gastric or duodenal ulcers (excluding ulcer scars)
•Concurrent presence of Barrett's esophagus
•A history of a poor response to H2RA or PPI given in the recommended dose for 8 weeks
•Other conditions considered by the attending physician to potentially affect the assessment of efficacy and safety

Key Dates

Start Date

November 1, 2011

Primary Completion Date

November 1, 2012

Completion Date

November 1, 2012

Last Updated

January 15, 2025

Enrollment

495

ACTUAL participants

Conditions

Erosive Esophagitis

Interventions

Lafutidine

DRUG

Famotidine

DRUG

Omeprazole

DRUG

A Study to Evaluate the Efficacy and Safety of BLI5100 in Patients With Erosive Esophagitis

NCT05587309

Erosive Esophagitis

View study

COMPLETEDPHASE1

A Study to Evaluate the Safety, Tolerability and Pharmacokinetics/Pharmacodynamics of Oral Doses of H008

NCT05050188

Erosive Esophagitis

View study

COMPLETEDPHASE3

Efficacy and Safety of Vonoprazan Compared to Lansoprazole in Participants With Erosive Esophagitis

NCT04124926

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 15, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

A Multi-center, Randomized, Double-blind Phase III Clinical Trial to Assess and Compare to the Efficacy and Safety of Lafutidine, Famotidine and Omeprazole-referenced in Korean Erosive Esophagitis Patients

Inclusion Criteria

Exclusion Criteria

A Study to Evaluate the Efficacy and Safety of BLI5100 in Patients With Erosive Esophagitis

A Study to Evaluate the Safety, Tolerability and Pharmacokinetics/Pharmacodynamics of Oral Doses of H008

Efficacy and Safety of Vonoprazan Compared to Lansoprazole in Participants With Erosive Esophagitis

Study to Evaluate the Efficacy and Safety of DWP14012 in Patients With Erosive Gastroesophageal Reflux Disease (Phase 3)

A Dose-finding Phase IIb Study With AZD0865 and Esomeprazole in GERD Patients With Erosive Esophagitis.

Efficacy Study of Ilaprazole to Treat Erosive Esophgitis